Reference ID: 3976113 - Celgene
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use VIDAZA safely and effectively. See full prescribing information for VIDAZA. VIDAZA(azacitidine for injection), for subcutaneous or intravenous useInitial Approval: 2004---------------------------RECENT MAJOR CHANGES---------------------------Dosage and Administration ( )7/2018----------------------------INDIC ATIONS AND USAGE---------------------------VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes.
For patients whose baseline counts are WBC <3.0 x109/L, ANC<1.5 x109/L, or platelets <75.0 x109/L, base dose adjustments on nadir counts and bone marrow biopsy cellularity
Download Reference ID: 3976113 - Celgene
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: